Novo Nordisk Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Incubators, ICT, Technology Initiatives, Partnerships, Investments, Acquisitions, Network Map
Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Novo Nordisk AS 2025" company profile has been added to ResearchAndMarkets.com's offering.
The report provides insights into company's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.
Novo Nordisk AS (Novo Nordisk), a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and delivering biological medicines for therapy areas for diabetes, haemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases, and obesity.
Its products include pre-filled delivery systems for insulin, glucagon hypokit, cartridge, needles, vials, insulin, estradiol for hormone replacement, recombinant drugs for haemophilia, glucagon, and oral antidiabetic agents.
The company offers its products to patients through brands such as NovoPen, FlexPen, Saxenda, and Ozempic. It markets products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East, and Australia.
The report provides information and insights into Novo Nordisk's tech activities, including:
Reasons to Buy
Key Topics Covered:
Companies Featured
For more information about this company profile visit https://www.researchandmarkets.com/r/g17rcz
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.